CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo

Leukemia

Volumn 29, Issue 6, 2015, Pages 1437-1441

  Gregory, G P ^a,b,c   Hogg, S J ^a,b   Kats, L M ^a,b   Vidacs, E ^a,b   Baker, A J ^a,b   Gilan, O ^a,b   Lefebure, M ^a,b   Martin, B P ^a,b   Dawson, M A ^a,b   Johnstone, R W ^a,b   Shortt, J ^a,b,c,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c SOUTHERN HEALTH   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 9; CYCLIN T1; DINACICLIB; MYC PROTEIN; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN MCL 1; RNA POLYMERASE II; FUSED HETEROCYCLIC RINGS; MCL1 PROTEIN, HUMAN; PYRIDINIUM DERIVATIVE;

APOPTOSIS; BURKITT LYMPHOMA; CANCER PROGNOSIS; CARBOXY TERMINAL SEQUENCE; DRUG EFFICACY; DRUG POTENCY; ENZYME PHOSPHORYLATION; HUMAN; IMMUNOBLOTTING; IN VIVO STUDY; LARGE CELL LYMPHOMA; LETTER; NONHUMAN; ONCOGENE MYC; OVERALL SURVIVAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION ELONGATION; ANIMAL; ANTAGONISTS AND INHIBITORS; B CELL LYMPHOMA; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; FIBROBLAST; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; APOPTOSIS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 9; FIBROBLASTS; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, INBRED C57BL; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTO-ONCOGENE PROTEINS C-MYC; PYRIDINIUM COMPOUNDS;

EID: 84930571469     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.10     Document Type: Letter

References (15)

1. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009; 114: 3533-3537.
2. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013; 121: 4021-4031.
3. Kanazawa S, Soucek L, Evan G, Okamoto T, Peterlin BM. c-MYC recruits P-TEFb for transcription, cellular proliferation and apoptosis. Oncogene 2003; 22: 5707-5711.
4. Marshall NF, Peng J, Xie Z, Price DH. Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J Biol Chem 1996; 271: 27176-27183.
5. Gargano B, Amente S, Majello B, Lania L. P-TEFb is a crucial co-factor for Myc transactivation. Cell Cycle 2007; 6: 2031-2037.
6. Cowling VH, Cole MD. The Myc transactivation domain promotes global phosphorylation of the RNA polymerase II carboxy-terminal domain independently of direct DNA binding. Mol Cell Biol 2007; 27: 2059-2073.
7. Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ et al. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev 2014; 28: 1800-1814.
8. Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010; 9: 2344-2353.
9. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533-538.
10. Mason KD, Vandenberg CJ, Scott CL, Wei AH, Cory S, Huang DCS et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci USA 2008; 105: 17961-17966.
11. Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 2005; 106: 1042-1047.
12. Lacrima K, Valentini A, Lambertini C, Taborelli M, Rinaldi A, Zucca E et al. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol 2005; 16: 1169-1176.
13. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
14. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202-208.
15. Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, Okamoto T et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev 2014; 28: 58-70.